Every Form 4 that Evolv Technologies Holdings, Inc. Warrant (EVLVW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EVLVW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EVLVW filings page.
Michael Ellenbogen, a director of Evolv Technologies Holdings, Inc., exercised stock options for 80,745 shares of Class A Common Stock at $0.24 per share and on the same date sold 80,745 shares at a weighted-average price of $5.94 under a Rule 10b5-1 trading plan. Following these transactions, he holds 2,083,961 shares directly, 151,135 shares indirectly through the Family Horizon Trust, and 897,014 stock options expiring on September 13, 2027.
Evolv Technologies Holdings director David Mounts Gonzales exercised restricted stock units that vested on June 17, 2026, converting them into 27,050 shares of Class A common stock. These RSUs represented a right to receive one share each and carried no expiration date.
After this compensation-related conversion, Gonzales directly holds 201,789 shares of Evolv Class A common stock. The filing does not show any open-market purchases or sales, only the exercise of equity awards previously granted to him.
Evolv Technologies Holdings, Inc. director Mark J. Sullivan exercised restricted stock units into common shares. On June 17, 2026, 27,050 RSUs vested in full and were converted into 27,050 shares of Class A common stock at no exercise price. Following this equity award vesting and conversion, he holds 242,628 Class A shares directly, with no same-day sale reported.
Evolv Technologies Holdings director Henrik Kuhl reported routine equity compensation activity. On June 18, 2026, he received a grant of 28,318 Restricted Stock Units, each representing one share of Class A common stock. These RSUs vest in full at the earlier of June 18, 2027 or the day immediately before the next annual meeting.
On June 17, 2026, 9,291 RSUs vested in full and were exercised into 9,291 shares of Class A common stock at no cash exercise price. Following these transactions, he directly holds 9,291 shares of Class A common stock from this exercise, along with the new 28,318-unit RSU award subject to future vesting.
Evolv Technologies Holdings director Kevin M. Charlton reported equity compensation and related share activity. He received a grant of 28,318 Restricted Stock Units (RSUs) on Class A common stock that will vest in full at the earlier of June 18, 2027 or the day immediately before the company’s next annual meeting. On June 17, 2026, a prior award of 27,050 RSUs vested in full, and these units were converted into the same number of Class A common shares, increasing his direct holdings to 359,010 shares. He also reports 44,081 Class A common shares held indirectly through an IRA.
Evolv Technologies Holdings director Richard A. Shapiro reported equity compensation activity in the form of restricted stock units (RSUs) and common stock. He received a grant of 28,318 RSUs, each representing a contingent right to one share of Class A common stock. These RSUs will vest in full at the earlier of June 18, 2027 or the day immediately preceding the company’s next annual meeting date.
Separately, 27,050 RSUs vested in full on June 17, 2026 and were exercised into 27,050 shares of Class A common stock, after which he held 79,565 shares directly. The filing also shows indirect holdings of 16,400 shares held by his spouse in a retirement plan, 22,500 shares held by a trust for which he has voting and dispositive power over the share-based assets, and 30,000 shares held by his spouse.
Evolv Technologies Holdings director Kimberly H. Sheehy reported equity compensation activity, not open-market trading. On June 18, 2026, she received a grant of 28,318 Restricted Stock Units, each representing a contingent right to one share of Class A common stock.
The new RSUs will vest in full at the earlier of June 18, 2027 or the day immediately preceding the issuer's next annual meeting date. On June 17, 2026, 27,050 RSUs vested and were exercised into 27,050 shares of Class A common stock. Following these transactions, Sheehy directly holds 170,085 common shares.
Evolv Technologies Holdings director Neil Glat reported equity compensation activity and an option-equivalent exercise. He received a grant of 28,318 Restricted Stock Units, each representing one share of Class A common stock. These RSUs will vest in full at the earlier of June 18, 2027 or the day immediately preceding the company’s next annual meeting date.
Separately, RSUs covering 27,050 shares vested in full on June 17, 2026 and were exercised into 27,050 shares of Class A common stock. Following these transactions, Glat directly holds 243,600 shares of Class A common stock and 28,318 outstanding RSUs.
Ellenbogen Michael reported acquisition or exercise transactions in this Form 4 filing.
Evolv Technologies Holdings, Inc. director Michael Ellenbogen reported an award of 28,318 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the company’s Class A common stock and has no expiration date.
The 28,318 RSUs will vest in full on the earlier of June 18, 2027 or the day immediately before the company’s next annual meeting date. Following this grant, Ellenbogen holds 28,318 RSUs directly, reflecting a compensation-related equity award rather than an open-market share purchase.
Evolv Technologies Holdings director Michael Ellenbogen exercised stock options and sold shares on the same day. He exercised options to acquire 80,745 shares of Class A Common Stock at an exercise price of $0.24 per share, then sold 80,745 shares at a weighted average price of $6.21 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan entered into on June 12, 2025. Following these transactions, he holds 2,083,961 shares of Class A Common Stock directly and 151,135 shares indirectly through the Family Horizon Trust, and retains 977,759 stock options.
Evolv Technologies Holdings director Michael Ellenbogen reported an exercise-and-sell transaction in Class A Common Stock. He exercised stock options for 80,745 shares at $0.24 per share and sold 80,745 shares at a weighted average price of $5.63 per share under a pre-arranged Rule 10b5-1 trading plan entered into on June 12, 2025, with sale prices ranging from $5.53 to $5.77. Following these transactions, he directly owns 2,083,961 shares and indirectly holds 151,135 shares through the Family Horizon Trust.
Evolv Technologies Holdings, Inc. Chief Financial Officer George C. Kutsor reported routine equity compensation activity. He exercised restricted stock units to acquire 138,888 shares of Class A common stock, then sold 51,448 shares at a weighted average price of $7.27 per share.
According to the filing, the sale was made solely to cover withholding taxes tied to RSU vesting, rather than as a discretionary stock sale. After these transactions, he directly holds 87,440 shares of Class A common stock and 277,778 RSUs, which vest in three equal annual tranches, each RSU representing a right to receive one share.
Evolv Technologies Holdings director Michael Ellenbogen exercised stock options and sold shares in a routine, pre-planned transaction. He exercised 80,745 stock options at an exercise price of $0.24 per share, receiving the same number of Class A Common shares.
On the same day, he sold 80,745 Class A Common shares at a weighted average price of $6.32 per share under a Rule 10b5-1 trading plan. After these transactions, he directly owned 2,083,961 Class A Common shares and indirectly held 151,135 shares through the Family Horizon Trust.
Evolv Technologies Holdings, Inc. director Michael Ellenbogen reported an open-market sale of 91,771 shares of Class A common stock at a weighted average price of $5.10 per share. The sale was made under a Rule 10b5-1 trading plan entered into on June 12, 2025.
The footnotes state that individual trades occurred between $5.04 and $5.17. After this sale, Ellenbogen directly owned 2,083,961 shares, and separately had 151,135 shares held indirectly through the Family Horizon Trust as a reported holding.
Kedzierski John reported acquisition or exercise transactions in this Form 4 filing.
Evolv Technologies Holdings President & CEO John Kedzierski received a grant of 373,831 Restricted Stock Units, each representing one share of Class A common stock at no cash cost. The RSUs vest in three equal annual installments beginning on March 2, 2027, and have no expiration date.
Marshall Robert E reported acquisition or exercise transactions in this Form 4 filing.
Evolv Technologies Holdings, Inc. reported that Chief Revenue Officer Robert E. Marshall received a grant of 186,915 Restricted Stock Units on March 2, 2026. Each RSU represents a contingent right to receive one share of Class A common stock. The award vests in three equal annual installments starting on March 2, 2027.
Kutsor George C reported acquisition or exercise transactions in this Form 4 filing.
Evolv Technologies Holdings, Inc. reported that Chief Financial Officer George C. Kutsor received an equity award of 186,915 Restricted Stock Units (RSUs) on March 2, 2026. Each RSU represents a contingent right to receive one share of Class A common stock and has no expiration date.
The RSUs were granted at no cash cost and will vest in three equal annual installments starting on March 2, 2027, tying the CFO’s compensation to the company’s long-term performance and continued service.
Evolv Technologies Holdings, Inc. reported that director Henrik Kuhl acquired 9,291 restricted stock units (RSUs) as a grant. Each RSU represents a contingent right to receive one share of Class A common stock and has no expiration date.
The RSUs will vest in full at the earlier of June 20, 2026 or the day immediately before the company’s next annual meeting. Following this grant, Kuhl holds a total of 9,291 RSUs directly.
Evolv Technologies Holdings, Inc. director Michael Ellenbogen exercised a stock option for 80,745 shares on February 17, 2026, converting options at an exercise price of $0.24 per share into Class A common stock. The same day, he sold 80,745 Class A shares in an open-market transaction at a weighted average price of $5.47 per share, with individual trades ranging from $5.39 to $5.65, under a pre-arranged Rule 10b5-1 trading plan entered into on June 12, 2025. Following these transactions, he directly owned 2,083,961 Class A shares and indirectly held 151,135 shares through Family Horizon Trust.